Akari Therapeutics released a CEO update discussing advances in antibody drug conjugates (ADCs) with their unique PH1 spliceosome-modulating payload, targeting difficult cancers like KRAS-driven tumors. The company presented promising preclinical data showing synergy between their ADC payload and KRAS inhibitors at ASCO 2026. Akari plans to start a Phase 1 clinical trial for their lead candidate AKTX-101 by mid-2027, aiming to address resistance issues and expand treatment options for solid tumors. This positions Akari as a key player in the evolving ADC landscape focusing on novel payload technologies.
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
